RS-2025-02122993

Development of an Extracellular Vesicle-Based *In Vivo* Macrophage Reprogramming Therapy for Inflammatory Bowel Disease with Enhanced Targeted Delivery Efficiency of NLRP3 ASO

SHIFTBIO.INC

SHIFTBIO

IMMUNOLOGY | Hit

Product Type	Gene/Cell Therapy & Nucleic acids
Indication	Inflammatory Bowel Diseases (Crohn's Disease, Ulcerative Colitis)
Target	NLRP3, CD47
MoA(Mechanism of Action)	*In Vivo* Macrophage Reprogramming via Targeted NLRP3 ASO Delivery
Competitiveness	• **Precision Targeting:** Selectively targets CD47+ pathological macrophages versus broad-acting small-molecule NLRP3 inhibitors. • **Superior Delivery:** SIRP-EV evades endolysosomal trapping, achieving enhanced cytosolic delivery efficiency. • **Disease-Modifying Approach:** Drives cellular reprogramming beyond cytokine blockade for differentiated IBD therapy.
Development Stage	Hit
Route of Administration	Intravenous administration